Veterinary Intravenous (IV) Solutions Market Report 2026

Veterinary Intravenous (IV) Solutions Market Overview

• Veterinary Intravenous (IV) Solutions market size has reached to $1.62 billion in 2025 • Expected to grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Rising Prevalence Of Animal Diseases Fuels Market Growth • Market Trend: Advancements In Veterinary IV Solutions For Respiratory Infections • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Veterinary Intravenous (IV) Solutions Market?

Veterinary intravenous (IV) solutions are sterile fluids administered directly into the bloodstream of animals through a vein, typically via an IV catheter. These solutions are used in veterinary medicine to treat dehydration and electrolyte imbalances, deliver medications, or provide nutrients. Veterinary intravenous (IV) solutions are essential for maintaining or restoring the proper fluid and electrolyte balance in animals, especially in illness, surgery, or trauma cases. The main product types of veterinary intravenous (iv) solutions are isotonic crystalloids, dextrose solutions, synthetic colloids, natural colloids, and parenteral nutrition. Isotonic crystalloids are intravenous (IV) fluids that have the same concentration of solutes as the blood, helping to maintain fluid balance in the body. The various animal types include companion animals and production animals. These are used by various end-users such as veterinary hospitals and clinics, research institutes, and others.

What Is The Veterinary Intravenous (IV) Solutions Market Growth Forecast?

The veterinary intravenous (iv) solutions market size is expected to see strong growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for advanced isotonic and colloid solutions, increasing adoption of parenteral nutrition in veterinary care, development of specialized iv solutions for critical care, rising awareness of fluid therapy benefits, expansion of veterinary emergency and critical care services. Major trends in the forecast period include development of advanced isotonic and balanced electrolyte solutions, increased use of synthetic and natural colloids, growth in parenteral nutrition solutions for companion and production animals, adoption of pre-mixed and ready-to-use iv solutions, expansion of veterinary critical care and emergency fluid therapy.

Global Veterinary Intravenous (IV) Solutions Market Segmentation

1) By Product: Isotonic Crystalloids, Dextrose Solutions, Synthetic Colloids, Natural Colloids, Parenteral Nutrition 2) By Animal Type: Companion Animals, Production Animals 3) By End-User: Veterinary Hospitals And Clinics, Research Institutes, Other End-Users Subsegments: 1) By Isotonic Crystalloids: Normal Saline (0.9% NaCl), Lactated Ringer's Solution, Dextrose In Water (D5W), Ringer's Solution, Balanced Electrolyte Solutions 2) By Dextrose Solutions: Dextrose 5% In Water (D5W), Dextrose 10% In Water (D10W), Dextrose 20% In Water (D20W), Dextrose 50% In Water (D50W) 3) By Synthetic Colloids: Hydroxyethyl Starch (HES), Dextran, Gelatins 4) By Natural Colloids: Albumin, Fresh Frozen Plasma (FFP), Blood Products 5) By Parenteral Nutrition: Total Parenteral Nutrition (TPN) Solutions, Partial Parenteral Nutrition Solutions, Lipid Emulsions, Amino Acid Solutions

What Are The Drivers Of The Veterinary Intravenous (IV) Solutions Market?

The increase in the prevalence of various animal diseases is expected to propel the growth of the veterinary intravenous (IV) solutions market going forward. Animal diseases refer to conditions or disorders that impair the health and function of animals. The common animal diseases are anthrax, leptospirosis, rabies, canine distemper, heartworm disease, and more. The increase in the prevalence of various animal diseases is driven by several factors, including intensive farming practices, wildlife encroachment, and antibiotic resistance. Veterinary intravenous solutions are essential for rehydrating animals affected by dehydration-inducing diseases, such as gastroenteritis or severe infections, by ensuring optimal hydration and supporting overall health outcomes. For instance, in May 2025, according to the World Organisation for Animal Health (WOAH), a France-based intergovernmental animal health body, outbreaks of avian influenza in mammals more than doubled last year compared with 2023, with 1,022 reported outbreaks across 55 countries compared to 459 outbreaks in 2023, indicating a significant rise in disease prevalence across multiple species. Therefore, the increase in the prevalence of various animal diseases is driving the growth of the veterinary intravenous (IV) solutions industry. The increasing spending on animal health products is expected to propel the growth of the veterinary intravenous (IV) solutions market going forward. Animal health products refer to medications, supplements, and treatments used to maintain or improve the health and well-being of animals. The increasing spending on animal health products is driven by factors such as rising pet ownership, growing awareness of animal health, advancements in veterinary care, and the need for better disease prevention and treatment options. Veterinarian IV solutions help to increase spending on animal health products by meeting urgent medical demands and advancing veterinary care. For instance, in March 2024, according to the Republic of Estonia Agency of Medicines, an Estonia-based regulatory authority, in 2023, the veterinary medicinal products market increased by 6.9%, reaching $20.54 million (18.6 million euros) up from USD 19.21 million (17.40 million euros) in 2022. Therefore, the increasing spending on animal health products is driving the growth of the veterinary intravenous (IV) solutions industry.

Key Players In The Global Veterinary Intravenous (IV) Solutions Market

Major companies operating in the veterinary intravenous (iv) solutions market are Merck & Co. Inc., Baxter International Inc., Zoetis Inc., Fresenius Kabi AG, Elanco Animal Health Incorporated, B. Braun Melsungen AG, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol SA, Norbrook Laboratories Limited, Ceva Santé Animale, Revival Animal Health Inc., Aromor Animal Health, Jorgensen Laboratories LLC, Pharmacosmos AS, Sykes Veterinary International Pty Ltd., Rusoma Laboratories Private Limited, Patterson Companies Inc., NexGen Veterinary, Soxa Formulations & Research Pvt. Ltd

Global Veterinary Intravenous (IV) Solutions Market Trends and Insights

Major companies operating in the veterinary intravenous (IV) solutions market are focusing on developing advanced products such as fluoroquinolone to help improve efficacy and safety profiles. Fluoroquinolones are a powerful class of antibiotics used in human and veterinary medicine to treat various bacterial infections that can be managed carefully to minimize the risk of resistance and side effects. For instance, in April 2024, Elanco, a US-based pharmaceutical company, announced Pradalex, a pradofloxacin injection solution approved by the US Food and Drug Administration (FDA), a US-based health organization. The approval for swine is for the treatment of swine respiratory disease (SRD) associated with bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, streptococcus suis, and mycoplasma hyopneumoniae. Pradalex is a 3rd generation fluoroquinolone, ranked as a critically important antimicrobial. The drug's label includes a statement that it should be used only after considering other non-fluoroquinolone therapeutic options.

Regional Outlook

North America was the largest region in the veterinary intravenous (IV) solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Veterinary Intravenous (IV) Solutions Market?

The veterinary intravenous (IV) solutions market consists of sales of hypertonic solutions, isotonic solutions, and hypertonic solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.